20/20 Biolabs is trading 8.55% higher at $0.37, with no verified catalyst identified for the October 8 move. - The October 7 investor webinar was announced in advance, and its replay is available. - The broader market and biotech sector are under pressure, so they do not explain the stock’s rise. The cause remains uncertain.